Taking CAR-T target research as an example, the current target in clinical research is mainly focused on CD19. The proportion of CAR-T clinical trials targeting CD19 in China has exceeded 40%.There are fewer safe targets that can be used, which is a limitation of the CAR-T and monoclonal antibody and other drug fields in the future . The membrane protein array technology can be used to scan new target antigens on primary tumor cells to identify new targets that can be applied to drug discovery, so as to find new therapeutic targets, find key breakthrough points for the development of monoclonal antibody drugs and CAR-X fields, provide new ideas for drug design.
